WO2021029746A3 - 항-tie2 항체 및 이의 용도 - Google Patents

항-tie2 항체 및 이의 용도 Download PDF

Info

Publication number
WO2021029746A3
WO2021029746A3 PCT/KR2020/010910 KR2020010910W WO2021029746A3 WO 2021029746 A3 WO2021029746 A3 WO 2021029746A3 KR 2020010910 W KR2020010910 W KR 2020010910W WO 2021029746 A3 WO2021029746 A3 WO 2021029746A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
composition
tie2
vector
nucleic acid
Prior art date
Application number
PCT/KR2020/010910
Other languages
English (en)
French (fr)
Other versions
WO2021029746A2 (ko
Inventor
이은아
박범용
강누리
박천호
이영애
김도윤
이원섭
유진산
Original Assignee
주식회사 파멥신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 파멥신 filed Critical 주식회사 파멥신
Priority to JP2021561640A priority Critical patent/JP7447144B2/ja
Priority to MX2021012869A priority patent/MX2021012869A/es
Priority to AU2020329057A priority patent/AU2020329057A1/en
Priority to EP20851469.5A priority patent/EP3960763A4/en
Priority to CN202080042038.9A priority patent/CN113993897B/zh
Priority to US17/607,872 priority patent/US20220213201A1/en
Priority to CA3136975A priority patent/CA3136975A1/en
Priority to BR112021021057A priority patent/BR112021021057A2/pt
Priority to SG11202111656WA priority patent/SG11202111656WA/en
Publication of WO2021029746A2 publication Critical patent/WO2021029746A2/ko
Publication of WO2021029746A3 publication Critical patent/WO2021029746A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7014—(Neo)vascularisation - Angiogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)

Abstract

본 발명은 TIE2 (Tyrosine-protein kinase receptor TIE-2)에 특이적으로 결합하여 수용체의 인산화를 통해 혈관을 정상화(vessel normalization)하고, 안정화 (stabilization)시키는 기능을 보유한 항체와 관련된 것으로, 항-TIE2 항체, 이를 코딩하는 핵산, 상기 핵산을 포함하는 벡터, 상기 벡터로 형질전환된 세포, 상기 항체의 제조방법, 이를 포함하는 혈관안정화제 및 신생혈관형성(angiogenesis)과 관련된 질병의 치료용 조성물, 종양 또는 암 치료용 약학적 조성물 및 TIE2에 결합하는 항체 이외의 조성물과의 병용투여용 조성물에 관한 것이다.
PCT/KR2020/010910 2019-08-14 2020-08-14 항-tie2 항체 및 이의 용도 WO2021029746A2 (ko)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2021561640A JP7447144B2 (ja) 2019-08-14 2020-08-14 抗ｔｉｅ２抗体及びその用途
MX2021012869A MX2021012869A (es) 2019-08-14 2020-08-14 Anticuerpo anti-tie2 y uso del mismo.
AU2020329057A AU2020329057A1 (en) 2019-08-14 2020-08-14 Anti-TIE2 antibody and use thereof
EP20851469.5A EP3960763A4 (en) 2019-08-14 2020-08-14 ANTI-TIE 2 ANTIBODIES AND ITS USE
CN202080042038.9A CN113993897B (zh) 2019-08-14 2020-08-14 抗tie2抗体及其用途
US17/607,872 US20220213201A1 (en) 2019-08-14 2020-08-14 Anti-tie2 antibody and use thereof
CA3136975A CA3136975A1 (en) 2019-08-14 2020-08-14 Anti-tie2 antibody and use thereof
BR112021021057A BR112021021057A2 (pt) 2019-08-14 2020-08-14 Anticorpo anti-tie2 e uso do mesmo
SG11202111656WA SG11202111656WA (en) 2019-08-14 2020-08-14 Anti-tie2 antibody and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190099491 2019-08-14
KR10-2019-0099491 2019-08-14

Publications (2)

Publication Number Publication Date
WO2021029746A2 WO2021029746A2 (ko) 2021-02-18
WO2021029746A3 true WO2021029746A3 (ko) 2021-10-07

Family

ID=74571257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/010910 WO2021029746A2 (ko) 2019-08-14 2020-08-14 항-tie2 항체 및 이의 용도

Country Status (10)

Country Link
US (1) US20220213201A1 (ko)
EP (1) EP3960763A4 (ko)
JP (1) JP7447144B2 (ko)
KR (1) KR20210020839A (ko)
AU (1) AU2020329057A1 (ko)
BR (1) BR112021021057A2 (ko)
CA (1) CA3136975A1 (ko)
MX (1) MX2021012869A (ko)
SG (1) SG11202111656WA (ko)
WO (1) WO2021029746A2 (ko)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100125033A (ko) * 2009-05-20 2010-11-30 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
JP2011525104A (ja) * 2008-02-20 2011-09-15 アムジエン・インコーポレーテツド アンジオポエチン−１およびアンジオポエチン−２に対する抗体、ならびに、その利用
KR20140054303A (ko) * 2011-08-19 2014-05-08 리제너론 파아마슈티컬스, 인크. 항-Ｔｉｅ２ 항체 및 이의 용도
US20160222130A1 (en) * 2014-07-15 2016-08-04 Astellas Pharma Inc. Novel anti-human tie-2 antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525104A (ja) * 2008-02-20 2011-09-15 アムジエン・インコーポレーテツド アンジオポエチン−１およびアンジオポエチン−２に対する抗体、ならびに、その利用
KR20100125033A (ko) * 2009-05-20 2010-11-30 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
KR20140054303A (ko) * 2011-08-19 2014-05-08 리제너론 파아마슈티컬스, 인크. 항-Ｔｉｅ２ 항체 및 이의 용도
US20160222130A1 (en) * 2014-07-15 2016-08-04 Astellas Pharma Inc. Novel anti-human tie-2 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANSBURY MICHAEL J ET AL: "Production and characterization of a Tie2 agonist monoclonal antibody.", ANGIOGENESIS, KLUWER, DORDRECHT,, NL, vol. 4, no. 1, 1 January 2001 (2001-01-01), NL, pages 29 - 36, XP002212102, ISSN: 0969-6970, DOI: 10.1023/A:1016678828930 *

Also Published As

Publication number Publication date
EP3960763A4 (en) 2022-12-28
JP7447144B2 (ja) 2024-03-11
CN113993897A (zh) 2022-01-28
CA3136975A1 (en) 2021-02-18
SG11202111656WA (en) 2021-11-29
US20220213201A1 (en) 2022-07-07
JP2022544433A (ja) 2022-10-19
EP3960763A2 (en) 2022-03-02
WO2021029746A2 (ko) 2021-02-18
MX2021012869A (es) 2021-12-10
KR20210020839A (ko) 2021-02-24
AU2020329057A1 (en) 2021-11-04
BR112021021057A2 (pt) 2021-12-14

Similar Documents

Publication Publication Date Title
AU2018244916A1 (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
MX2019005125A (es) Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular.
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
TN2014000536A1 (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2016187220A3 (en) Anti-ror1 antibodies
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
WO2013173129A3 (en) Treatment of amd using aav sflt-1
MX2010005300A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
AR111497A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos
MX2017010763A (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
WO2019241893A3 (en) Anti-her3 antibody and uses thereof
WO2019175198A3 (en) Antibodies
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2019002664A (es) Proteina de union a antigeno contra her3.
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
MX2020005771A (es) Composicion y metodo para tratar el linfoma periferico de linfocitos t y el linfoma cutaneo de linfocitos t.
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
WO2021029746A3 (ko) 항-tie2 항체 및 이의 용도

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021561640

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3136975

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021021057

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020329057

Country of ref document: AU

Date of ref document: 20200814

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20851469

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020851469

Country of ref document: EP

Effective date: 20211123

ENP Entry into the national phase

Ref document number: 112021021057

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211020

NENP Non-entry into the national phase

Ref country code: DE